Company profile
Adicet Bio, Inc.
NASDAQ:ACETBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Prulacabtagene Leucel | phase1 | — | 3 | active |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (5)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04735471 | phase1 | terminated | 2021-03-04 | 2025-02-03 | Adicet Therapeutics | A Phase 1 Study of ADI-001 in B Cell Malignancies |
| NCT07100873 | phase1 | recruiting | 2025-10-10 | 2027-03-30 | Adicet Therapeutics | A Phase 1 Study of ADI-001 in Rheumatoid Arthritis |
| NCT06375993 | phase1 | enrolling_by_invitation | 2024-11-10 | 2026-12-01 | Adicet Therapeutics | A Phase 1 Study of Prulacabtagene Leucel (Prula-cel, Formerly ADI-001) in Autoimmune Disease |
| NCT07793435 | phase1_2 | not_yet_recruiting | 2026-09-01 | 2028-10-01 | Adicet Therapeutics | A Phase 1/2 Trial of ADI-212 in mCRPC |
| NCT06480565 | phase1_2 | active_not_recruiting | 2024-12-12 | 2026-06-01 | Adicet Therapeutics | A Phase 1/2 Trial of ADI-270 in ccRCC |
FDA applications (0)
No records yet.